Clinical Trial: A Real-World Study of Inavolisib in Patients With HR-Positive/HER2-Negative, PIK3CA-Mutated Advanced Breast Cancer

U.S., April 22 -- ClinicalTrials.gov registry received information related to the study (NCT07543250) titled 'A Real-World Study of Inavolisib in Patients With HR-Positive/HER2-Negative, PIK3CA-Mutated Advanced Breast Cancer' on April 15.

Brief Summary: A Multicenter, Observational Study on the Real-World Effectiveness and Safety of inavolisib Combined with Endocrine Therapy With or Without a CDK4/6 Inhibitor in Patients with HR-Positive/HER2-Negative, PIK3CA-Mutated Advanced Breast Cancer.

Study Start Date: May 16

Study Type: OBSERVATIONAL

Condition: Breast Cancer

Intervention: DRUG: Inavolisib in Combination With ET

Inavolisib in Combination With ET

DRUG: Inavolisib in Combination With ET+CDK4/6i

Inavolisib in Combination With E...